A convenient procedure for the preparation of 5,6-dihydro-6-nitro-5-phenylfuro[2,3-d]pyrimidin-4(3H)-ones and 5-phenylfuro[2,3-d]pyrimidin-4(3H)-ones
作者:Daniel Dauzonne、Anne Adam-Launay
DOI:10.1016/s0040-4020(01)92249-5
日期:1992.4
Z-(2-chloro-2-nitroethenyl)benzenes with 4,6-dihydroxypyrimidine provides 5,6-dihydro-6-nitro-5-phenylfuro[2,3-d]pyrimidin-4(3H)-ones at room temperature. Involving the same starting materials, but using DBU in refluxing ethanol instead of triethylamine, the so far unknown 5-phenylfuro[2,3-d]pyrimidin-4(3H-ones are obtained
Z-(2-氯-2-硝基乙烯基)苯与4,6-二羟基嘧啶的三乙胺促进的缩合反应提供5,6-二氢-6-硝基-5-苯基呋喃[2,3-d]嘧啶-4(3 H)-在室温下一个。使用相同的起始原料,但在回流的乙醇中使用DBU代替三乙胺,获得了迄今未知的5-苯基呋喃[2,3-d]嘧啶-4(3 H -ones)
Heteroaromatic NMDA receptor modulators and uses thereof
申请人:Cadent Therapeutics, Inc.
公开号:US10626122B2
公开(公告)日:2020-04-21
Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.
HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
申请人:Cadent Therapeutics, Inc.
公开号:EP3386591B1
公开(公告)日:2020-06-24
Compounds Useful in HIV Therapy
申请人:GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
公开号:US20200325147A1
公开(公告)日:2020-10-15
The invention relates to compounds of Formula (I), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.